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Abstract 
Growing evidence suggests that small vesicles actively released from cells may 
encapsulate transcriptional regulators and RNA molecules. Their ability to interact with 
neighbouring cells and/or with distant cells through biological fluids, makes them a medium 
through which intercellular exchange of information can happen. Recently, membrane 
vesicles, which include exosomes and microvesicles, gained a place amongst the vast 
group of angiogenic mediators. In the present review we discuss the potential relevance of 
these vesicles in physiological and pathological situations of angiogenesis as well as their 
mechanism of action. 
Abbreviations 
EVs, extracellular vesicles; MVBs, multivesicular bodies; ESCRT, exosomal sorting 
complex required for transport; DCs, dendritic cells; lncRNA, long noncoding RNA; miRNA, 
microRNA; MMP, matrix metalloproteinases; EGFRvIII, epidermal growth factor receptor 
vIII; VEGF, vascular endothelial factor; VEGF-R2, vascular endothelial factor-receptor 2; 
FGF, fibroblast growth factor; EGF-R, epidermal growth factorreceptor; IL-3, interleukin-3; 
IL-6, interleukin-6; IL-8, interleukin-8; TIMP-1 and -2, tissue inhibitors of metallo-
proteinases-1 and -2; ECFCs, endothelial colony-forming cells; NOS, nitric oxide synthase; 
ASCs, mesenchymal stromal cells from adipose tissue; PDGF, platelet derived growth 
factor; SCF, stem cell factor; MSCs, mesenchymal stromal cells; MCP-1, monocyte 
chemoattractant protein-1; SCID, severe combined immune deficiency; HMEC, human 
microvascular endothelial cells. 
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1. Introduction
Angiogenesis is a tightly regulated process that is essential not only throughout embryo
development, but also during the maintenance of vascular homeostasis in adult
organisms. Moreover, new vessel formation is also critical in several processes involving
tissue regeneration. Angiogenesis is normally initiated after preliminary destabilization of
pre-existing vessels, whereby, the proliferation and migration of endothelial cells cause
endothelial sprouting, canalization and eventually stabilization of the vessel wall leading to
the formation of new blood vessels [1]. Complex arrays of soluble factors together with
cell-to-cell and cell-to-matrix interactions modulate angiogenesis at a physiological level.
However, an altered form of angiogenesis may occur in several pathological conditions
including tumours as well as in various inflammatory states whereby the process may be
dysregulated leading to an abnormally enhanced or reduced level of new vessel formation.
Recently, vesicles released by cells have also been implicated in the array of mediators 
involved in angiogenesis. The phenomenon of vesiculation has been for long time 
considered a hallmark of cell injury and vesicles present in biological fluids or in culture 
medium were retained as fragments of dying cells. More recently, it has been discovered 
that perfectly healthy cells also release vesicles and exploit them as vehicles for sharing 
biologically active molecules with other cells in a paracrine and/or endocrine fashion [2]. 
This new mechanism of cell-to-cell communication relies on vesicle mediated transfer of 
bio-active lipids, proteins, receptors and nucleic acids. In particular, the transfer of 
transcriptional regulators and non-coding RNAs may account for the epigenetic changes 
induced by these vesicles in recipient cells. Interestingly, communications mediated by 
vesicles have emerged to be a well preserved evolutionary mechanism in the three life 
kingdoms of protists, plants and fungi [3], [4], [5], [6], [7] as well as in invertebrates [8] and 
vertebrates [9]. In mammalians this mechanism of inter-cellular communication has been 
involved in multiple biological, physiological, and pathological processes including 
angiogenesis [10]. 
2. Extracellular vesicle biogenesis and function
Two main classes of non-apoptotic vesicles released by cells have been identified [2].
Firstly, exosomes originate from invaginations of endosomal membranes of multivesicular
bodies (MVBs) which fuse with the plasma-membrane leading to exosome release.
Secondly, vesicles formed on the cell surface through budding of the plasma-membrane
ensuing in extracellular release. For this latter class of vesicles, the literature has attributed
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various names including: ectosomes, shedding vesicles, microvesicles and microparticles. 
Moreover, they have also been entitled on the basis of their function or tissue of origin for 
example: tolerosomes, cardiosomes, and prostatosomes [11], [12], [13]. Despite the 
divergence in the formation of these two classes of vesicles, they have similar functions, 
similar mechanisms of membrane budding as well as several overlapping characteristics. 
Furthermore, cells frequently release them concomitantly and therefore it has been 
proposed to collectively identify them as “extracellular vesicles” (EVs) [11]. 
The assembly of EVs depends on the accumulation of their constituents in small 
membrane domains that bud into MVBs to form exosomes, or on cell surface to form 
shedding vesicles. These small membrane domains are assembled from several lipids 
such as cholesterol, phospholipids, sphingomyelins, ceramide and proteins 
[12], [13], [14], [15]. One such protein is Alix, an accessory protein of the endosomal 
sorting complex required for transport (ESCRT) which has been implicated in the transfer 
of proteins to these small membrane domains [13]. Furthermore, due to its 
multiple protein-binding sites, Alix has also been associated with multifunctional activities 
in exosome biogenesis [14]. ESCRT, originally considered specific for exosome 
biogenesis, has also been recently identified to participate in the assembly and release of 
vesicles shed through plasma-membrane budding [13]. Furthermore, biogenesis of shed 
vesicles requires in addition, binding to plasma-membrane anchors as well as high-
ordered polymerization of specific cytoplasmic proteins which do not interact with MVB 
membranes during exosome assembly [16]. Nevertheless, the molecular contents of 
exosomes and shedding microvesicles are similar and include heat-shock 
proteins, cytoskeleton proteins and several cell specific proteins and RNA species [17]. 
Moreover, the EV plasma membrane frequently expresses molecules and receptors 
representative of the cell of origin. 
The functional role of EVs in intercellular communication is dependent on their interaction 
with cells present in the surrounding extracellular milieu. Released EVs may interact with 
the originator cells therefore acting as autocrine mediators and with other cell types thus 
acting as paracrine/endocrine mediators. Furthermore, the interaction can be mediated 
either by direct fusion or through specific receptors leading to the fusion of EVs with the 
recipient cell's plasma-membrane causing release of their contents intracellularly. The 
mechanism of uptake may vary depending on the origin of EVs as well as on the target 
cells. We found for instance that EVs derived from proangiogenic progenitors express 
mainly L-selectin for the interaction with endothelial cells[18], whereas those derived 
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from mesenchymal stem cells mainly express integrins and CD44 that enhance their 
binding to epithelial cells [19]. Furthermore, the uptake of EVs from the placenta was due 
to the expression of syncytin-1, which belongs to a family of mammalian fusogens [20]. 
Studies based on lipid fusion assay have also shown that EV uptake by dendritic 
cells(DCs) depends on fusion of cholesterol rich plasma membrane microdomains as well 
as cytoskeleton activation [21], [22]. An alternative mechanism by which EVs can deliver 
their content to target cells is through receptor-mediated [23] or receptor-independent 
clathrin-mediated endocytosis and micropinocytosis [24]. Once fused or internalized, EVs 
release their biologically active contents rich in proteins [25], [26], or oncogenic 
products [27] that can induce functional changes in recipient cells. Moreover, EVs also 
carry transcription factors and nucleic acids such as mRNA, long non-coding RNA 
(lncRNA) and microRNA (miRNA) [28], [29], [30] that could induce transient or 
persistent epigenetic modifications in recipient cells. This form of transport of active 
molecules by EVs is advantageous as the encapsulation provides protection from 
degrading enzymes in the microenvironment. Finally, EVs may also act as a signalling-
complex without the need of internalization. An example of this mechanism was provided 
by Raposo et al. [31], who demonstrated that vesicles released from B lymphocytes could 
activate T cells by presenting the MHC-II-peptide complex expressed on their surface. 
3. EV modulation of angiogenesis
Most of the studies investigating the angiogenic properties of EVs have been performed on
tumour released vesicles. Kim et al. [32] for instance, showed that sphingomyelin
expressed on tumour EVs stimulated endothelial cell migration and angiogenesis.
Moreover, tumour-derived EVs, rich in matrix metalloproteinases (MMP) [33] as well as in
the extracellular MMP inducer CD147 [34], could have a role in the degradation
of extracellular matrix proteinsnecessary for the angiogenic process.
The EV membrane is enriched in tetraspanins such as Tspan8, that together with 
other adhesion molecules, has been linked with the endothelial uptake of vesicles [35]. As 
a result, an upregulated expression of VEGF, VEGF-R2 and von Willebrand factor (vWF) 
has been observed in recipient endothelial cells [36], eventually leading to the stimulation 
of vessel sprouting and branching [37]. Furthermore, the mutated oncogenic epidermal 
growth factor receptor (EGFRvIII) carried by EVs released by glioma cells was recently 
attributed to enhance the production of VEGF and VEGF-R2 through the activation 
of MAPKand Akt pathways in endothelial cells [27]. In addition, it has also been reported 
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that tumour-derived EVs may contain and deliver not only various growth factors, pro-
angiogenic modulatory proteins such as VEGF, FGF, EGF-R, IL-6, IL-8, and angiogenin, 
and anti-angiogenic proteins like TIMP-1 and -2, but also nucleic acids such as mRNAs 
which may be translated into active proteins within recipient cells [38]. 
Interestingly, we have also found that EVs with proangiogenic properties can be released 
by a subset of renal cancer stem cells defined on the basis that: they were positive for the 
expression of stem cell markers such Nestin, Nanog and Oct3–4; they exhibited the ability 
to induce serially transplantable tumours starting from a number of cells as low as 100 
cells; and they had the capability to generate clones and to grow in spheres [26]. These 
vesicles were found to be enriched with pro-angiogenic mRNA, miRNA and proteins 
(MMP2/9, angiopoietin 1, ephrin A3, FGF and VEGF) that could favour tumour 
vascularization and lung metastasis by priming endothelial cells [26]. 
Hypoxia is a factor that favours the accumulation of pro-angiogenic molecules in tumour 
derived EVs [39]. It has been shown for instance that hypoxia enhances the 
compartmentalization of pro-angiogenic miRNAs such as the miR-210 in tumour EVs [40], 
or miR-126 and miR-296 in EVs derived from proangiogenic progenitors [41]. 
Proangiogenic progenitors are bone marrow derived cells present in the 
circulation [42] that have been implicated in different angiogenic conditions such as tissue 
healing, cancer and inflammation. These cells have been shown to exist in two different 
populations as described by Yoder et al. [43]. One population also known as 
proangiogenic progenitors or as endothelial colony-forming cells (ECFCs) expresses 
endothelial markers such as vWF, KDR, CD31, CD146, CD105, CD144 and UEA-1 but not 
haematopoietic markers such as CD45 and CD14. The other population is considered to 
be of myeloid progenitor origin and expresses the haematopoietic markers CD45 and 
CD14. 
During an injury, proangiogenic progenitors accumulate at the affected site and act mainly 
in a paracrine manner releasing cytokines, growth factors, as well as EVs. For instance, 
we found that these cells released EVs that induced neo-angiogenesis both in vitro and in 
vivo through horizontal transfer of functional mRNA to quiescent endothelial cells [29]. The 
transfer of mRNA and its translation into protein was confirmed through the transduction of 
GFP protein in endothelial cells that were exposed to proangiogenic progenitor derived-
EVs containing GFP-mRNA. Moreover, the biological activity demonstrated by the EVs 
was significantly reduced when inactivating their RNA content. Subsequent studies further 
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revealed the presence of miRNAs as well in EVs derived from proangiogenic progenitors 
which also exhibited angiogenic activity relevant to their function [41]. Taken together 
these experiments suggest that RNA delivered by EVs contributes towards the angiogenic 
potential of proangiogenic progenitor-derived vesicles. 
Endothelial cells on the other hand, may also release EVs that contribute towards vascular 
homeostasis through autocrine and/or paracrine activities. It has in fact been shown that 
endothelial EVs may potentially transfer the protein Delta-like ligand 4 to neighbouring 
endothelial cells that may promote angiogenesis by blocking the Notch signal [44]. More 
recently, we have also found that in an inflammatory microenvironment rich 
in interleukin IL-3, endothelial cell-derived EVs transfer the activated form of the functional 
transcriptional factor STAT5 to neighbouring cells. 
4. EVs in angiogenic tissue regeneration
In the context of tissue regeneration, the concept of stem/progenitor cell EVs exhibiting
properties to activate angiogenesis has been investigated in several studies. We
demonstrated that EVs derived from proangiogenic progenitors elicit a pro-angiogenic
phenotype in quiescent human micro- and macrovascular endothelial cells when
internalized [29]. The size of these vesicles as observed by Nanosight analysis
and electron microscopy was in the nanometre range of 60–130 nm (Fig. 1A) and they
were mainly sorted from the cell surface [41]. Moreover, cytofluorimetric analysis showed
that these EVs were positive for endothelial markers such as α4 and β1 integrins, L-
selectin, CD105, CD31 and VEGFR1 (Fig. 1B) but not P-selectin, CD42b (platelet
markers) and CD14 (monocyte marker).
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Fig. 1. Angiogenic potential of proangiogenic progenitor-derived EVs. Panel A: nanoparticle tracking analysis 
of purified proangiogenic progenitor-derived EVs. Inset: representative micrograph of transmission electron 
microscopy of purified proangiogenic progenitor-derived EVs showing a spheroid shape (white bar = 100 
nm). Panel B: representative cytofluorimetric analysis showing the expression of CD31 and VEGFR1 by 
proangiogenic progenitor-derived EVs. The green lines represent the control isotype antibody. Panel C and 
D: representative capillary-like structure formation by HMEC plated on Matrigel after 24 hour incubation at 
37 °C in the absence (C) or presence (D) of EVs (original magnification, ×500). EPC-derived EVs induced 
formation of vessel-like structures.Panel E: representative laser doppler analysis of SCID mice with acute 
hindlimb ischemic injury induced by ligation and resection of the left femoral artery and treated with EVs. 
The images were obtained before surgery, immediately after surgery and 7 days after surgery in untreated 
animals (control) and in mice treated with EVs. EV treatment restored perfusion which was absent when 
RNA in EVs was inactivated by RNase treatment. 
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Further investigations revealed that α4 and β1 integrins as well as L-selectin present on 
the EV membrane interacted with endothelial cells and were therefore instrumental for 
their cellular uptake. Post-internalization, these EVs did not only stimulate endothelial cell 
proliferation, but also increased their resistance to apoptosis and instigated the formation 
of capillary-like structures when culturing EV-treated cells on Matrigel [29] (Fig. 1C, D). 
Moreover, inhibition of these surface molecules (integrins and selectins), with blocking 
antibodies and proteases, prevented the internalization of EVs as well as the 
consequential pro-angiogenic effects induced by them in vitro[29]. In vivo, we observed 
that, injecting severe combined immunodeficient mice (SCID) subcutaneously with EVs 
incorporated in a Matrigel matrix together with human endothelial cells, favoured the 
organization of endothelial cells in canalized vessels. Furthermore, as various studies on 
EV internalization have revealed the transfer of mRNAs related to nitric oxide 
synthase (NOS) and PI3K/AKT signalling pathways from proangiogenic progenitors to 
endothelial cells to be critical in the formation of new blood vessels, it can be speculated 
that the observed effects may be due to the horizontal transfer of RNA carried by EVs from 
proangiogenic progenitors to endothelial cells [29]. These experiments prompted us to 
evaluate whether proangiogenic progenitor-derived EVs may prevent and favour recovery 
from ischemia/reperfusion injury. 
In a rat experimental setting of renal ischemia–reperfusion injury, we observed that EVs 
derived from proangiogenic progenitors, when injected intravenously, were localized within 
tubular cells and in peritubular capillaries therefore favouring functional and morphological 
protection of the kidney from acute injury. These EVs not only had a stimulatory effect on 
the proliferation rate of tubular epithelial cells and increased their resistance to apoptosis 
but also decreased the infiltration of leukocytes. In addition, they also prevented the 
development of tubulointerstitial fibrosis, glomerulosclerosis as well as impeded vascular 
rarefaction [41]. This resulted in the inhibition of the progression of the injury 
towards chronic renal failure which is normally evident after an acute ischemia/reperfusion 
injury. The healing effects of EVs observed were mainly attributed to the reprogramming of 
hypoxic resident renal cells to a more regenerative phenotype through the delivery of 
RNAs that they are enriched in. In fact, the pro-angiogenic miRNAs: miR-126 and miR-296 
carried by EVs were shown to be contributors towards the protective effects observed [41]. 
Interestingly, reducing the EV miRNA content, either by Dicer knock-down in 
proangiogenic progenitors or through the use of specific antagomirs together with 
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inactivating RNAs, by treating vesicles with elevated concentrations of RNases, inactivated 
the observed EV biological activities [41]. 
EVs derived from proangiogenic progenitors have been also shown to be effective in the 
treatment of experimental peripheral artery disease. In fact, EVs from proangiogenic 
progenitors have been shown to favour neovascularizationin a murine model of severe 
hind-limb ischemia obtained in SCID mice by ligation and resection of the left femoral 
artery [45]. Analysis by laser-doppler flowmetry showed not only an increase in hind-limb 
perfusion but also a reduction in the ischemic damage after EV treatment (Fig. 1E). The 
contribution of RNAs carried by EVs was investigated by treating mice either with EVs that 
had RNA inactivated or with EVs released from Dicer knock-down proangiogenic 
progenitors (in order to achieve miRNA depletion). In these experimental conditions we 
observed that neovascularization, endothelial repair and regeneration were significantly 
reduced further confirming the role of RNA in biologically active EVs. 
Apart from proangiogenic progenitors, the human mesenchymal stromal cellsfrom adipose 
tissue (ASCs) have also been reported to release EVs that exhibit a pro-angiogenic 
potential. Eirin et al. [46] demonstrated that ASC-derived EVs are enriched with several 
types of RNAs that target gene products that modulate several cellular pathways including 
angiogenesis. We found in our study that EVs released from ASCs carried several 
angiogenic factors such as c-kit, MFG-E8, SCF, APRIL, artemin, angiopoietin-like factor 
and the matrix metalloproteinase MMP-20 which facilitated endothelial cell migration [47]. 
Furthermore, several pro-angiogenic miRNAs including miR-17, miR-21, miR-126, miR-
130a, miR-210 and miR-296 were also discovered to be enriched in these EVs [48]. 
Interestingly, we also observed that the microenvironment plays an important role in 
modulation of EV cargo and their biological activity. For example, ASC stimulation 
with platelet derived growth factor (PDGF), which is involved in the formation of new 
vessels after damage, not only increased the secretion of EVs but also altered 
their proteomic content [47] and enhanced angiogenesis in vitro and in vivo (Fig. 2A–C). 
For instance, expression of some pro-angiogenic molecules that were absent in basal 
conditions were observed after PDGF stimulation including c-kit, a receptor present in 
endothelial and haematopoietic progenitor cells, and its ligand SCF [47]. Experiments in 
which SCF or c-kit was blocked, significantly reduced but not completely abrogated the 
pro-angiogenic effects of EVs, therefore suggesting that a concomitant action of different 
mediators is involved. The enhanced expression of MMP2 and MMP9 in EVs derived from 
PDGF-treated ASCs possibly favours the migration of endothelial cells required for the 
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formation of new vessels. In fact, the invasiveness of EV-treated endothelial cells was 
significantly reduced by Batimastat, an inhibitor of matrix metalloproteinases. In contrast, 
stimulation of ASCs with bFGF induced the release of vesicles which exhibited stabilizing 
effects on vessel growth [48] (Fig.2D). For instance, several angiogenic proteins 
expressed in EVs including MFG-E8, artemin, APRIL, angiopoietin-like factor and MMP-20 
were down-regulated and expression of angiogenesis modulators such as TRANCE and 
MMP-7 were upregulated. Furthermore, profiling of mature miRNAs present in EVs 
revealed the down-regulation of several pro-angiogenic miRNAs after bFGF treatment 
including miR-194, miR-21, and miR-224 that target TRANCE and miR-210 that targets 
MMP-7. These vesicles also showed a diverse angiogenic potential: the number of vessels 
formed by HMEC stimulated with EVs released from bFGF-treated ASCs was significantly 
lower than in control EVs, but these vessels were larger in size (Fig. 2D). Furthermore, 
these vessels contained smooth muscle actin positive cells, suggesting formation of more 
stabilized vessels. Since there was a down-regulation of the pro-angiogenic miR-21 and 
an up-regulation of the anti-angiogenic miR-223 in EVs from bFGF-treated ASCs, we have 
also studied their potential role/effects in the bFGF-induced changes of vesicle angiogenic 
properties. Experiments based on transfection with miR-21 mimic or with miR-223 
antagomir suggested that, changes in the balance of the expression of these two miRNAs 
in vesicles moderate their angiogenic ability. Taken together these data suggest that the 
microenvironment may influence the ability of EVs to induce new vessel formation by 
altering their expression of pro- and anti-angiogenic factors [47], [48]. Interestingly, we also 
studied the potential damaging effects of metabolic environmental cues. In particular we 
observed that obesity impacts the pro-angiogenic potential of ASC-derived EVs by 
impairing VEGF, MMP-2 and miR-126 content [49]. This implies that although the 
observed function of ASC-EVs may make them suitable for use in regenerative medicine, 
the study of EVs released in different pathological contexts is crucial to assess their proper 
therapeutic applications. 
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Fig. 2. PDGF and bFGF influence on angiogenic properties of ASC-derived EVs. EVs obtained in basic 
conditions (b-EV) and EVs obtained after ASC stimulation with PDGF (PDGF-EV) or bFGF (FGF-EV) were used 
in in vitro and in vivo models of angiogenesis. Representative images of in vivo vessel formation within 
subcutaneously injected Matrigel containing HMEC (sections stained by trichrome method; arrows indicate 
red blood cell containing vessels, original magnification ×250); insets show capillary-like structure formation 
in vitro on Matrigel (phase contrast microscopy, original magnification ×250): (A) non-stimulated HMEC 
(control), (B) HMEC stimulated with b-EVs, (C) HMEC stimulated with PDGF-EVs, (D) HMEC stimulated with 
FGF-EVs. 
Bone marrow-derived mesenchymal stromal cells (MSCs) were also shown to possess a 
pro-angiogenic effect. MSCs have been demonstrated to exert cardiovascular protection 
and to have potential regenerative properties in cardiovascular medicine [50]. The 
beneficial effect of MSCs in this context has mainly been attributed to paracrine factors 
and several studies have reported the contribution of EVs as well. For instance, Lai et 
al. [51] reported that EVs isolated from supernatant of human MSCs reduced the size of 
the myocardial infarct when infused in a Langendorff mouse heart model of 
ischemia/reperfusion injury. In a successive experiment, the same group demonstrated 
that the observed beneficial effects of MSC-derived EVs could be attributed to the 
enzymes they carry which are essential for the ATP generating stage of glycolysis to 
increase ATP production, as well as, in the activation of the PI3K/Akt signalling that 
confers cardioprotection, and a decreased state of oxidative stress, therefore ameliorating 
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overall cardiac performance [52]. Furthermore, Bian et al. [53] also reported the 
cardioprotective properties of EVs whereby they showed that EVs released from human 
bone marrow MSCs, when injected into myocardium in a rat model of acute myocardial 
infarction, induced migration and proliferation of endothelial cells and promoted 
angiogenesis in the ischemic area, thereby limiting the size of the infarct [53]. 
EVs derived from the human umbilical cord MSCs have also recently been implicated to 
exhibit pro-angiogenic activity. For instance, it has been shown that EVs released by 
umbilical cord MSCs induced migration, proliferation and angiogenesis in vitro by 
activating the Wnt/β-catenin pathway [54]. This pro-angiogenic effect was reversed by 
the β-catenin inhibitor ICG-001 and abrogated by the knockdown of Wnt4. Furthermore, 
Chen et al. [55]demonstrated that, in hypoxic conditions, umbilical cord-derived MSCs 
produced EVs enriched in pro-angiogenic factors such as VEGF, 
VEGFR2, monocyte chemoattractant protein-1 (MCP-1), angiogenin, IL-6, Tie-2/TEK 
and insulin-like growth factor (IGF). It therefore seems that a hypoxic microenvironment 
may also play a role in the enrichment of EVs with proangiogenic factors as the same was 
observed by Salomon et al.[56] for EVs isolated from placenta-derived MSCs. 
Furthermore, a recent study by Anderson et al. [57] who carried out a comprehensive 
proteomic analysis of MSC EVs identified a key role played by the NFkB signalling 
pathway in EV mediated angiogenesis. 
5. Conclusions
Angiogenesis is a well-regulated process that plays a crucial role in embryo development,
vascular homeostasis in mature organisms, and during tissue regeneration. An altered
process of angiogenesis has been implicated in various pathological conditions including
tumours and inflammation. Besides soluble factors, EVs have recently emerged as
mediators of autocrine/paracrine activity in new vessel formation.
Angiogenic EVs are released from different cell types. Their biological activity, depending 
on the cell of origin, the content they carry, and the situation in which they are released in, 
may have either beneficial or detrimental effects. The microenvironment, in 
particular hypoxia, may modulate the release as well as the quality of their cargo. Although 
EVs released by normal endothelial cellsmay have a role in endothelial homeostasis, 
those derived from tumour or inflammatory cells could promote an enhanced angiogenic 
response pathological in nature. On the other hand, EVs released from stem/progenitor 
cells have been shown to play a more therapeutic role by limiting ischemic injuryand 
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contributing towards tissue regeneration. Therefore, there have been suggestions to apply 
stem/progenitor cell derived EVs as a potential tool in therapy. Nevertheless, it should be 
acknowledged that native EVs are heterogeneous in nature and in content which, albeit 
may be advantageous as they may deliver multiple molecules that could have a synergistic 
effect on angiogenesis. However, this heterogeneity may present a problem during the 
standardization process of EV preparations for eventual therapeutic application. It is 
therefore important to identify and categorize the active molecules carried by these EVs, 
as this may allow the generation of engineered EVs enriched with potential angiogenic 
molecules as well as specific surface molecules that would facilitate endothelial targeting. 
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